Dr Reddys Laboratories Limited Friday said its profit after tax for the quarter ended September 30 was up by 77 per cent to Rs 504 crore against Rs 387.6 crore in the second quarter of FY18.
According to a press release issued by the drug maker, revenues for the quarter under discussion was up by seven per cent to Rs 3798 crore.
It was Rs 3546 crore in the same quarter last fiscal.
On the results, Co-chairman and CEO, G V Prasad said, "I am encouraged by our performance and progress in the second quarter. Our continuous focus on execution, operational efficiency and cost optimization are showing results.
Looking ahead, our priority will be to resolve pending regulatory issues, and continue to work on execution and cost structures that will enable affordable medicines for more patients."
Revenues from Global Generics segment in the Q2 was reported at Rs 3050 crore a year-on-year growth of 7 per cent over the same quarter last year, primarily driven by contributions from Emerging Markets, India and favorable forex.
Revenues from Pharmaceutical Services and Active Ingredients was at Rs 600 crore in the second quarter with seven per cent growth over the Q2 of FY18.
Disclaimer: No Business Standard Journalist was involved in creation of this content
